Viral hemorrhagic fever

Korea University College of Medicine Identifies Hantavirus in South Korea Using a New Rapid Test, Paving Way for Early Outbreak Control

Retrieved on: 
Thursday, February 29, 2024
Viral hemorrhagic fever, Virology, Hope, Branches of microbiology, Prevalence, Eisenmenger syndrome, Journal, Genomics, Issue 1, Shrew, Orthohantavirus, Research, DNA, Public, Vaccine

SEOUL, South Korea, Feb. 29, 2024 /PRNewswire/ -- Orthohantaviruses, highly transmissible zoonotic pathogens, are notorious for causing hemorrhagic fever with renal syndrome (HFRS) in Eurasia and hantavirus cardiopulmonary syndrome in the Americas. With a significant impact on public health, they have been extensively researched for effective outbreak control and intervention strategies. Gyeonggi Province in South Korea has reported a significant number of HFRS cases, making it a critical area for epidemiological surveillance and understanding the genomic diversity of orthohantaviruses.

Key Points: 
  • With a significant impact on public health, they have been extensively researched for effective outbreak control and intervention strategies.
  • Notably, the study showcased the application of Flongle sequencing, an innovative, cost-efficient, and rapid method, for detecting HTNV genomes.
  • "We developed a rapid and sensitive on-site diagnostic using a nanopore-based Flongle chip with a reasonable cost of around $100.
  • Title of original paper: High-resolution phylogeographical surveillance of Hantaan orthohantavirus using rapid amplicon-based Flongle sequencing, Republic of Korea

Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda

Retrieved on: 
Thursday, October 19, 2023
Biomedical Advanced Research and Development Authority, Guinea, Makerere University Walter Reed Project, Sabin Vaccine Institute, Vaccine, Family, Human services, Kenya Medical Research Institute, Administration for Strategic Preparedness and Response, Viral hemorrhagic fever, Organization, BARDA, United States Department of Health and Human Services, Research, Volunteering, Administration, Development, Epidemic, Disease, Clinical trial, Blood, Safety, Office of Inspector General, U.S. Department of Health and Human Services, Polio, Marburg virus disease, Medical device, Pharmaceutical industry

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus. Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today.

Key Points: 
  • WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute has launched a Phase 2 clinical trial for its vaccine candidate against the lethal Marburg virus.
  • “Makerere University Walter Reed Project (MUWRP) is delighted to partner with the Sabin Vaccine Institute to launch the clinical testing for a preventive Marburg vaccine,” says Dr. Mwesigwa.
  • In addition to the current trial in Uganda and Kenya, Sabin plans to conduct a similar Phase 2 clinical trial for Marburg in the U.S.
  • Sabin has also initiated plans for a Phase 2 Sudan ebolavirus vaccine clinical trial in Uganda and Kenya.

Crimean-Congo haemorrhagic fever – why this tick-borne virus could become more common in richer countries

Retrieved on: 
Tuesday, June 20, 2023
Viral hemorrhagic fever, West Nile virus, Human, Depression, Bleeding, Myalgia, Lyme disease, Dengue fever, Rift Valley fever, Arthralgia, CCHFV, Ribavirin, Infection, Fever, Injury, Crimea, Livestock, Global health, Research, Medicine, Tick, Hepatitis C, Hyalomma, Dizziness, Animal, Climate change, Fever Dream, Risk, Blood, Cattle, Rabbit, WHO, World, Meat, Death, Virus, Disease, World Health Organization, Vaccine, Renting, Animal husbandry, Poultry farming

However, richer countries, such as the UK, will also probably be on the receiving end of emerging infectious disease threats as the country warms.

Key Points: 
  • However, richer countries, such as the UK, will also probably be on the receiving end of emerging infectious disease threats as the country warms.
  • Dengue, a virus transmitted by mosquitoes, is becoming more widely reported in European countries, particularly in some parts of Italy and France.
  • The West Nile virus, which is also spread by mosquitoes, has been common across many states in the US, with typically more than 1,000 cases reported each year.
  • Another virus shifting to new locations is the Crimean-Congo haemorrhagic fever virus (CCHFV), which is transmitted by ticks.
  • CCHFV is a serious pathogen – typically between 10-40% of people who contract the virus will die from it.

Should we be worried?

    • The Hyalomma tick is not currently established in the UK, and so the threat, for now, is very low.
    • Still, there are many other types of ticks in the UK, including those responsible for causing Lyme disease, which are usually found on vegetation.
    • There is concern from the WHO and other health experts about the global spread of this Hyalomma tick.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Global Viral Hemorrhagic Fever Treatment Market to Surpass USD 2.20 Billion By 2031| Growth Market Reports

Retrieved on: 
Monday, June 12, 2023
Vaccine, Yellow fever, Human, Ebola, Completeness, Prevalence, Rift Valley fever, Infection, Fever, Hantavirus pulmonary syndrome, Key, Viral hemorrhagic fever, Hygiene, VHF, Government, Blood, HPS, Animal, Lymphocytic choriomeningitis, Lassa fever, Research, Study, Disease, Retail, Online shopping, Video game, RVSV-ZEBOV vaccine, Medication, Others, Growth, Ribavirin, Forecast

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.

Key Points: 
  • The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics.
  • Moreover, it provides crucial strategies that are helping market players to expand their market share.
  • For Any Questions on This Report: https://growthmarketreports.com/enquiry-before-buying/3851
    On the basis of region, the global viral hemorrhagic fever treatment market is classified as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • North America is projected to dominate the global market because it has a well-established R&D laboratory.

Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits

Retrieved on: 
Wednesday, April 19, 2023
Public, Viral, Global health, Infection, International Health Regulations, RNA, Viral hemorrhagic fever, Marburg virus disease, Diagnosis, PCR, Disease, World Health Organization, Vaccine

LONDON, April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.

Key Points: 
  • LONDON, April 19, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotech company focused on the detection of immune responses to and diagnosis of viral diseases, announced today that it has entered into an agreement for the distribution of Marburg Virus PCR testing kits.
  • The Marburg Virus Real Time PCR Kit is an in-vitro diagnostic test, based on real-time PCR technology, for the detection of ribonucleic acid (better known as RNA) from the Marburg Virus.
  • Our Marburg Virus PCR testing kit is a significant step forward in our mission to improve global health."
  • The Marburg Virus Disease is a highly virulent disease which causes hemorrhagic fever and requires assessment under the International Health Regulations by the World Health Organization.

Amadou Sall Honored with Prestigious Barka Award and Ten Diaspora Leaders Receive Luminaire Awards at African Diaspora Investment Symposium

Retrieved on: 
Monday, March 27, 2023
Dengue fever, Education, Face, Value chain, Senior, Bill & Melinda Gates Foundation, COVID-19, Luminary (podcast network), ADN, Ernst & Young, Side platform, Partner (business rank), Infection, Viral hemorrhagic fever, Government, McNeil Consumer Healthcare, Barka, Epidemic, Entrepreneurship, The Luminaire, City, Santa Clara University, Investment, Love, CFO, Pasteur Institute of Dakar, WHO, Health, Environment, World Health Organization, Film industry, Management, Arbovirus, Chikungunya, Ujamaa, Sanofi, Stripe

SILICON VALLEY, Calif., March 27, 2023 /PRNewswire-PRWeb/ -- The African Diaspora Network (ADN) demonstrated its dedication to leading diaspora philanthropy, investment, and innovation at the just concluded African Diaspora Investment Symposium (ADIS) with its diverse panel discussions, keynote addresses, and the presentation of its Barka and Luminarie awards to distinguished Africans and Diasporans.

Key Points: 
  • The African Diaspora Network demonstrated its dedication to leading diaspora philanthropy, investment, and innovation at the just concluded African Diaspora Investment Symposium (ADIS) with its diverse panel discussions, keynote addresses, and the presentation of its Barka and Luminarie awards to distinguished Africans and Diasporans.
  • This year, the Barka Award was presented on Thursday the 23rd of March 2023 to Dr. Amadou Alpha Sall for his leadership and contribution to healthcare development in Senegal and Africa.
  • "I can't think of a more deserving recipient of the Barka Award than my dear colleague and friend, Amadou Sall.
  • The Barka and Luminaires awardees were honored during a private awards dinner held on Thursday, March 23, 2023 at Santa Clara University.

Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine

Retrieved on: 
Wednesday, September 14, 2022
Disability, Safety, Development, Biomedical Advanced Research and Development Authority, Human, Department, Sabin, Policy, Twitter, Office of Inspector General, U.S. Department of Health and Human Services, Virus, United States Department of Health and Human Services, BARDA, Administration, Sabin Vaccine Institute, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, Primate, Viral hemorrhagic fever, Human services, Vaccine, Solution, DRC, Marburg virus disease, Ecosystem, Research, GLOBE, Animal, Ebola River, Disease, Death

The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.

Key Points: 
  • The Sabin Marburg vaccine is the only candidate currently slated for a Phase 2 clinical trial.
  • The latest tranche of funds enables Sabin to conduct a randomized, blinded, placebo-controlled clinical trial among adults in the U.S. to further evaluate the safety and the efficacy of the Marburg vaccine candidate and advance non-clinical vaccine dosing studies.
  • In 2019, BARDA awarded Sabin a multi-year contract valued at $128 million to further the development of vaccines against two lethal viruses: Marburg and Ebola Sudan.
  • The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation.

Fluid Management Systems Market - Global Trajectory & Analytics to 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 18, 2022
Other Manufacturing, Manufacturing, Swine influenza, Lists of countries and territories, Infection, Disposable product, Hospital, CAGR, Hepatitis A, Hospital-acquired infection, Viral hemorrhagic fever, Meningitis, HIV/AIDS, Immunodeficiency, STD, System, Zika virus, Fluid, Malaria, Growth, IV, Patient safety, Fever Dream, Tuberculosis, Vertically transmitted infection, Pet, Pharmaceutical industry

The "Fluid Management Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fluid Management Systems - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • the global market for Fluid Management Systems estimated at US$11.1 Billion in the year 2022, is projected to reach a revised size of US$18.5 Billion by 2026, growing at a CAGR of 13.2% over the analysis period.
  • This segment currently accounts for a 32.5% share of the global Fluid Management Systems market.
  • The U.S. Market is Estimated at $3.6 Billion in 2022, While China is Forecast to Reach $2.4 Billion by 2026
    The Fluid Management Systems market in the U.S. is estimated at US$3.6 Billion in the year 2022.

Pew Supports 10 Latin American Scientists Pursuing Biomedical Research

Retrieved on: 
Tuesday, June 14, 2022
Chromatin, Biomedicine, Research, Cell, Mitochondrion, Knowledge, Biomedical sciences, Fellows, Biomedical Research, Animal, Viral hemorrhagic fever, RNA, Berkeley, CEO, National Advisory Committee for Aeronautics, Alexander Fleming Biomedical Sciences Research Center, The Pew Charitable Trusts, Gene, University, Acute myeloid leukemia, Laboratory, DNA, Health, Medical research, Parent, Mother, Medicine, Infection, Bacteria, Leukemia, Biochemistry, Biophysics, Cancer, Mentorship, Hospital, Drug, Vaccine, Toy, Pew

PHILADELPHIA, June 14, 2022 /PRNewswire/ -- The Pew Charitable Trusts today announced the 2022 class members of the Pew Latin American Fellows Program in the Biomedical Sciences.

Key Points: 
  • PHILADELPHIA, June 14, 2022 /PRNewswire/ -- The Pew Charitable Trusts today announced the 2022 class members of the Pew Latin American Fellows Program in the Biomedical Sciences.
  • The fellows will work under the mentorship of prominent biomedical scientists, including alumni of the Pew Scholars Program in the Biomedical Sciences, the Pew-Stewart Scholars Program for Cancer Research, and the Pew Latin American Fellows Program.
  • "Biomedical research is a global effort requiring an imaginative, diverse community of scientists," said Susan K. Urahn, Pew's president and CEO.
  • Fellows who choose to return to Latin America to launch their own research labs will receive additional funding from Pew.